Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma

被引：7
作者：
Qin, Shu-Kui [1 ]
Jin, Jie [2 ]
Guo, Jun [3 ]
Wang, Jin-Wan [4 ,5 ]
Zhou, Fang-Dian [6 ]
Huang, Yi-Ran [7 ]
Ren, Xiu-Bao [8 ]
Ye, Ding-Wei [9 ]
Pan, Sharon [10 ]
Sajben, Peter [10 ]
Wang, Qiao [11 ]
机构：
[1] Nanjing Bayi Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[2] Peking Univ, Hosp 1, Dept Urol, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China
[5] Peking Union Med Coll, Beijing, Peoples R China
[6] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[7] Shanghai Renji Hosp, Dept Urol, Shanghai, Peoples R China
[8] Tianjin Med Univ, Canc Inst & Hosp, Dept Biol Treatment, Tianjin, Peoples R China
[9] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China
[10] Pfizer Inc, New York, NY 10017 USA
[11] Pfizer Global Res & Dev, Shanghai, Peoples R China
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 18期
关键词：
Chinese; metastasis; renal cell carcinoma; sunitinib; targeted therapy; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS; SURVIVAL; HYPERTENSION; BIOMARKERS; SORAFENIB; AXITINIB; THERAPY;
D O I：
10.2217/fon-2017-0733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We report the first prospective study of sunitinib for metastatic renal cell carcinoma (mRCC) in China. Methods: Chinese mRCC patients received first-line sunitinib 50 mg daily (4/2 regimen). Overall survival (OS), progression-free survival (PFS), objective response rate and safety were assessed. Potential efficacy biomarkers were explored in post hoc analyses. Results: Median PFS was 61.7 weeks; median OS was 133.4 weeks; objective response rate was 31.1%. Most frequent adverse events (AEs) were: hand-foot syndrome (63.8%), decreased white blood cell count (52.4%), fatigue (51.4%) and decreased platelet count (51.4%). AEs were identified that predicted longer PFS and OS. Conclusion: Sunitinib showed efficacy and manageable AE profile in treatment-naive Chinese mRCC patients. Larger prospective studies are required to confirm identified AEs as predictors of efficacy.
引用
收藏
页码：1835 / 1845
页数：11
相关论文
共 32 条
[31]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[32]   Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma [J].
Tomita, Yoshihiko ;
Shinohara, Nobuo ;
Yuasa, Takeshi ;
Fujimoto, Hiroyuki ;
Niwakawa, Masashi ;
Mugiya, Soichi ;
Miki, Tsuneharu ;
Uemura, Hirotsugu ;
Nonomura, Norio ;
Takahashi, Masayuki ;
Hasegawa, Yoshihiro ;
Agata, Naoki ;
Houk, Brett ;
Naito, Seiji ;
Akaza, Hideyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (12) :1166-1172
1234